Monopar Therapeutics (NASDAQ:MNPR) Rating Lowered to “Sell” at Wall Street Zen

Monopar Therapeutics (NASDAQ:MNPR) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Sunday.

Several other brokerages have also recently weighed in on MNPR. BTIG Research raised their price objective on Monopar Therapeutics from $117.00 to $133.00 and gave the company a “buy” rating in a report on Wednesday, August 12th. UBS Group set a $125.00 target price on Monopar Therapeutics in a report on Thursday, July 23rd. HC Wainwright increased their price target on Monopar Therapeutics from $105.00 to $125.00 and gave the company a “buy” rating in a research report on Wednesday, July 22nd. Cantor Fitzgerald downgraded Monopar Therapeutics from an “overweight” rating to a “neutral” rating and raised their price target for the company from $109.00 to $119.00 in a research note on Thursday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Monopar Therapeutics in a research report on Friday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Monopar Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $118.67.

Monopar Therapeutics Trading Up 3.1%

Shares of MNPR opened at $116.49 on Friday. Monopar Therapeutics has a 12 month low of $29.18 and a 12 month high of $124.82. The firm has a fifty day simple moving average of $97.23 and a 200 day simple moving average of $71.85. The stock has a market capitalization of $781.65 million, a price-to-earnings ratio of -53.68 and a beta of 1.47.

Monopar Therapeutics (NASDAQ:MNPR) last released its earnings results on Wednesday, August 12th. The company reported ($0.62) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.64) by $0.02. As a group, research analysts predict that Monopar Therapeutics will post -2.96 earnings per share for the current fiscal year.

Institutional Trading of Monopar Therapeutics

Several institutional investors have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. acquired a new position in Monopar Therapeutics in the 3rd quarter valued at $28,000. BNP Paribas Financial Markets lifted its holdings in shares of Monopar Therapeutics by 100.6% during the third quarter. BNP Paribas Financial Markets now owns 696 shares of the company’s stock worth $57,000 after buying an additional 349 shares in the last quarter. Meeder Asset Management Inc. bought a new stake in shares of Monopar Therapeutics in the fourth quarter valued at about $65,000. JPMorgan Chase & Co. boosted its position in shares of Monopar Therapeutics by 1,821.0% in the second quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock valued at $69,000 after acquiring an additional 1,821 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of Monopar Therapeutics in the second quarter valued at about $80,000. 1.83% of the stock is currently owned by institutional investors.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.